Perspective Therapeutics (NASDAQ:CATX) Coverage Initiated at Piper Sandler

Analysts at Piper Sandler started coverage on shares of Perspective Therapeutics (NASDAQ:CATX) in a research note issued on Thursday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $16.00 price target on the stock. Piper Sandler’s price target indicates a potential upside of 183.19% from the company’s previous close.

A number of other equities analysts also recently issued reports on the company. HC Wainwright increased their price target on Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. BTIG Research reiterated a “buy” rating and set a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 13th. Truist Financial began coverage on shares of Perspective Therapeutics in a research note on Monday, November 24th. They issued a “buy” rating and a $12.00 price target on the stock. UBS Group reduced their price objective on shares of Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Finally, Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Friday, January 30th. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $11.86.

Perspective Therapeutics Stock Performance

CATX stock opened at $5.65 on Thursday. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $6.16. The stock has a market cap of $420.01 million, a price-to-earnings ratio of -6.28 and a beta of 1.75. The stock’s 50-day moving average price is $3.42.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics during the 4th quarter worth $28,000. nVerses Capital LLC acquired a new position in Perspective Therapeutics in the 4th quarter valued at about $31,000. AXQ Capital LP boosted its holdings in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after purchasing an additional 2,481 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at approximately $35,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Perspective Therapeutics in the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.